FLNA vs MLCI Comparison

Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.

Mount Logan Capital Inc operates as emerging asset management and investment firm focused on investing in public and private debt securities in the North American market. The company's reporting segments include asset management and insurance. The company through its subsidiaries, earns management and incentive fees and servicing fees for providing investment management, monitoring and other services to investment vehicles and advisers. The Asset Management segment comprises all fee generating activities. The Insurance Solutions segment, which derives maximum revenue, consists of two product lines within the insurance business, LTC and MYGA.